JP7210612B2 - 抗ａベータ抗体及びその使用 - Google Patents

抗ａベータ抗体及びその使用 Download PDF

Info

Publication number
JP7210612B2
JP7210612B2 JP2020566267A JP2020566267A JP7210612B2 JP 7210612 B2 JP7210612 B2 JP 7210612B2 JP 2020566267 A JP2020566267 A JP 2020566267A JP 2020566267 A JP2020566267 A JP 2020566267A JP 7210612 B2 JP7210612 B2 JP 7210612B2
Authority
JP
Japan
Prior art keywords
antibody
seq
sequence
cdr2
cdr1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020566267A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021525512A (ja
JP2021525512A5 (enExample
Inventor
フォン－シュン シエ
ツ－アン スー
サンタイ シェン
チュアン シー
Original Assignee
ナショナル ヘルス リサーチ インスティチューツ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ナショナル ヘルス リサーチ インスティチューツ filed Critical ナショナル ヘルス リサーチ インスティチューツ
Publication of JP2021525512A publication Critical patent/JP2021525512A/ja
Publication of JP2021525512A5 publication Critical patent/JP2021525512A5/ja
Application granted granted Critical
Publication of JP7210612B2 publication Critical patent/JP7210612B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020566267A 2018-05-30 2019-05-29 抗ａベータ抗体及びその使用 Active JP7210612B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678080P 2018-05-30 2018-05-30
US62/678,080 2018-05-30
PCT/US2019/034259 WO2019231957A1 (en) 2018-05-30 2019-05-29 Anti-abeta antibodies and uses thereof

Publications (3)

Publication Number Publication Date
JP2021525512A JP2021525512A (ja) 2021-09-27
JP2021525512A5 JP2021525512A5 (enExample) 2022-05-20
JP7210612B2 true JP7210612B2 (ja) 2023-01-23

Family

ID=68694402

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566267A Active JP7210612B2 (ja) 2018-05-30 2019-05-29 抗ａベータ抗体及びその使用

Country Status (8)

Country Link
US (1) US11084873B2 (enExample)
EP (1) EP3801618A4 (enExample)
JP (1) JP7210612B2 (enExample)
KR (1) KR102523019B1 (enExample)
CN (1) CN112601550B (enExample)
CA (1) CA3100896C (enExample)
TW (1) TWI721440B (enExample)
WO (1) WO2019231957A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101325972B (zh) * 2005-12-12 2020-06-16 Ac免疫有限公司 具有治疗性质的Aβ1-42特异性单克隆抗体
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
EP2527369A3 (en) * 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
CA2705509A1 (en) * 2007-11-14 2009-05-22 Forerunner Pharma Research Co., Ltd. Diagnosis and treatment of cancer using anti-gpr49 antibody
EP2207568B1 (en) * 2007-11-16 2017-05-31 The Rockefeller University Antibodies specific for the protofibril form of beta-amyloid protein
WO2011016238A1 (en) * 2009-08-06 2011-02-10 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
US20150315267A1 (en) 2012-12-07 2015-11-05 Thierry Bussiere A method of reducing brain amyloid plaques using anti-ab antibodies
WO2014151747A1 (en) * 2013-03-15 2014-09-25 Ramot At Tel Aviv University Ltd. Methods and compositions with immune therapy for treatment of dementia
RU2699717C2 (ru) * 2014-04-18 2019-09-09 Дзе Ресёч Фаундэйшен Фор Дзе Штат Юниверсити Ов Нью-Йорк Гуманизированные антитела к антигену Томсена-Фриденрайха
KR102776187B1 (ko) * 2015-11-09 2025-03-07 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타에서의 n-말단 에피토프 및 이에 형태적으로-선택적인 항체
EP4063858A1 (en) * 2016-03-14 2022-09-28 Biogen International Neuroscience GmbH Antibody-dependent cell-mediated phagocytosis assay for reliably measuring uptake of aggregated proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. Neuroimmunol.，1998年，Vol. 88，pp.85-90
PLOS ONE，2014年，Vol. 9, Issue 3, e90857

Also Published As

Publication number Publication date
US20190367593A1 (en) 2019-12-05
CN112601550B (zh) 2023-12-08
CN112601550A (zh) 2021-04-02
KR102523019B1 (ko) 2023-04-18
EP3801618A1 (en) 2021-04-14
KR20210041535A (ko) 2021-04-15
JP2021525512A (ja) 2021-09-27
EP3801618A4 (en) 2022-07-27
TWI721440B (zh) 2021-03-11
TW202033549A (zh) 2020-09-16
US11084873B2 (en) 2021-08-10
WO2019231957A1 (en) 2019-12-05
CA3100896C (en) 2023-08-29
CA3100896A1 (en) 2019-12-05
AU2019277171A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
JP7532571B2 (ja) 抗Ｎ３ｐＧｌｕアミロイドベータペプチド抗体およびその使用
JP7610279B2 (ja) アルファ－シヌクレインに対する抗体およびその用途
JP6261621B2 (ja) アルファ−シヌクレイン抗体及びその使用
CA2812865C (en) Phosphospecific antibodies recognising tau
JP6449441B2 (ja) ＦｃＲｎ特異的ヒト抗体及びこれを含む自己免疫疾患治療用組成物
AU2018312441B2 (en) Antibody binding active alpha-synuclein
US20100104577A1 (en) Methods and materials related to anti-a (beta) antibodies
JP7210612B2 (ja) 抗ａベータ抗体及びその使用
CN114945592A (zh) 抗-α-突触核蛋白单克隆抗体及其使用方法
JP2026503664A (ja) 抗ａベータ抗体を用いた神経障害の治療方法
HK40040248A (en) Anti-abeta antibodies and uses thereof
HK40040248B (zh) 抗-乙型淀粉样蛋白抗体及其用途
EA041243B1 (ru) Антитела к бета-амилоидному пептиду n3pglu и их применение
EA048027B1 (ru) АНТИТЕЛА К α-СИНУКЛЕИНУ И ИХ ПРИМЕНЕНИЯ
BR122024022779A2 (pt) Molécula de ácido nucleico, célula de mamífero, processo para produzir um anticorpo anti-n3pg ab

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220512

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220512

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220512

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221118

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221213

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230111

R150 Certificate of patent or registration of utility model

Ref document number: 7210612

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250